Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 15/20 | 0.66 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982577 | 0.83 | RPS6KA3 (0.59) | RPS6KA3RPS6KA2TDP1ALDH1A1 | |
| SCHEMBL1982055 | 0.75 | RPS6KA3 (0.64) | RPS6KA3 | |
| SCHEMBL1978106 | 0.66 | RPS6KA2 (0.64) | RPS6KA3RPS6KA2 | |
| SCHEMBL18247596 | 0.64 | TDP1 (0.53) | TDP1HSP90AA1ESR2KDM4EALDH1A1 | |
| SCHEMBL28144432 | 0.63 | TDP1 (0.47) | TDP1HSP90AA1ESR2KDM4E | |
| SCHEMBL824437 | 0.62 | TDP1 (0.49) | TDP1HSP90AA1ESR2KDM4EALDH1A1 | |
| SCHEMBL31140562 | 0.61 | TDP1 (0.49) | TDP1HSP90AA1ESR2KDM4EALDH1A1 | |
| SCHEMBL12325952 | 0.61 | KDM4E (0.64) | TDP1KDM4EALDH1A1HPGD | |
| SCHEMBL18662767 | 0.61 | ACSS2 (0.61) | TDP1KDM4EALDH1A1HPGD | |
| SCHEMBL3088114 | 0.61 | RPS6KA3 (0.67) | RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509979-B1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INT (DE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2509979-B1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INT (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9073926-B2 | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073926-B2 | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073926-B2 | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| EP-2509979-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | Boehringer Ingelheim International GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071725-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071725-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | PKD1, PAH, JAK2 | RPS6KA3 955/4885RPS6KA2 1164/4885TDP1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.